FY2024 EPS Estimates for Vincerx Pharma Lowered by Analyst

Vincerx Pharma, Inc. (NASDAQ:VINC) – Stock analysts at Leerink Partnrs dropped their FY2024 earnings estimates for Vincerx Pharma in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.50) for the year, down from their prior forecast of ($0.38). The consensus estimate for Vincerx Pharma’s current full-year earnings is ($0.38) per share. Leerink Partnrs also issued estimates for Vincerx Pharma’s Q4 2024 earnings at ($0.13) EPS and FY2025 earnings at ($0.32) EPS.

Vincerx Pharma (NASDAQ:VINC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17).

Separately, Leerink Partners cut their price objective on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Vincerx Pharma Price Performance

Shares of NASDAQ VINC opened at $0.30 on Friday. The company’s fifty day moving average is $0.52 and its 200-day moving average is $0.64. Vincerx Pharma has a twelve month low of $0.29 and a twelve month high of $9.37.

Institutional Investors Weigh In On Vincerx Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new stake in Vincerx Pharma in the 2nd quarter valued at $1,610,000. Vanguard Group Inc. increased its stake in Vincerx Pharma by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after buying an additional 153,575 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Vincerx Pharma by 359.1% in the 2nd quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after buying an additional 256,967 shares during the last quarter. 44.02% of the stock is owned by institutional investors.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.